Clinical Trial Update: A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM [Phase 2]

View source ↗

Summary

A Phase II randomized trial evaluating gemcitabine with or without ramucirumab for second-line mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma

Drugs mentioned

• Cyramza (ramucirumab)
• Gemzar (gemcitabine)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED